BGB 290

Drug Profile

BGB 290

Alternative Names: BeiGene-290; BGB-290; PARP-Tankyrase programme - BeiGene; PARPi - BeiGene

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioblastoma; Solid tumours
  • Phase I Cancer

Most Recent Events

  • 09 Aug 2017 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed, Second-line therapy or greater) in USA (PO)
  • 09 Aug 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in USA (PO)
  • 05 Jun 2017 Initial efficacy and adverse events data from a phase I trial in Solid tumours presented at the American Society for Clinical Oncology Annual Meeting (ASCO-2017) (9217847; 3251119)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top